Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share

Shares of Relypsa Inc RLYP were trading higher by more than 2 percent at $28.60 early Thursday morning after the Daily Mail reported the company may be a potential acquisition target.

The Daily Mail reported that "rumors from across the Pond" suggest that AstraZeneca plc (ADR) AZN is eyeing another acquisition just weeks after acquiring ZS Pharma. The publication suggested that the company's CEO Pascal Soriot "now wants to take out" Relypsa –- ZS Pharma's biggest competitor.